CSTL vs. PGNY, NHC, PACS, GRAL, AHCO, TDOC, VRDN, AVAH, PNTG, and CDNA
Should you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Progyny (PGNY), National HealthCare (NHC), PACS Group (PACS), Grail (GRAL), AdaptHealth (AHCO), Teladoc Health (TDOC), Viridian Therapeutics (VRDN), Aveanna Healthcare (AVAH), The Pennant Group (PNTG), and CareDx (CDNA). These companies are all part of the "healthcare" industry.
Castle Biosciences vs.
Castle Biosciences (NASDAQ:CSTL) and Progyny (NASDAQ:PGNY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.
Progyny has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.
Castle Biosciences has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.
92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 6.5% of Castle Biosciences shares are held by company insiders. Comparatively, 9.4% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Castle Biosciences and Castle Biosciences both had 6 articles in the media. Progyny's average media sentiment score of 1.47 beat Castle Biosciences' score of 1.34 indicating that Progyny is being referred to more favorably in the news media.
Progyny has a net margin of 5.03% compared to Castle Biosciences' net margin of 1.95%. Progyny's return on equity of 11.36% beat Castle Biosciences' return on equity.
Castle Biosciences presently has a consensus price target of $37.00, suggesting a potential upside of 110.23%. Progyny has a consensus price target of $23.45, suggesting a potential upside of 8.19%. Given Castle Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Castle Biosciences is more favorable than Progyny.
Progyny received 7 more outperform votes than Castle Biosciences when rated by MarketBeat users. Likewise, 70.34% of users gave Progyny an outperform vote while only 64.63% of users gave Castle Biosciences an outperform vote.
Summary
Progyny beats Castle Biosciences on 13 of the 17 factors compared between the two stocks.
Get Castle Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Castle Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CSTL) was last updated on 6/8/2025 by MarketBeat.com Staff
